The Food and Drug Administration (FDA) has approved Arbli™, an oral suspension formulation of losartan potassium. Arbli, an angiotensin II receptor blocker, is indicated for the treatment of ...

Mankind Pharma and other domestic companies have launched generic versions of the popular diabetes drug Empagliflozin at ...

The cohort comprised 9729 patients — 1087 in the dabigatran group, 3046 in the rivaroxaban group, 3043 in the apixaban group, and 2553 in the edoxaban group. Mean patient ages ranged from 75.8 years ...

College of Biological Science and Engineering, Fuzhou University, Fujian, China PR (Y.Z., D.W., C.Y., Mingdong Huang, P.X.). College of Chemistry, Fuzhou University ...

With the emergence and approval of other new oral anticoagulants such as dabigatran and rivaroxaban, the role of and place in therapy for all of these new agents will have to be clearly delineated.